Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue
Operating expenses:    
Research and development, net of reimbursements 7,700 6,635
General and administrative 8,938 2,962
Total operating expenses 16,638 9,597
Loss from operations (16,638) (9,597)
Other income:    
Interest income - net 700 927
Total other income 700 927
Net loss $ (15,938) $ (8,670)
Net loss per share of common stock – basic (in Dollars per share) $ (0.51) $ (0.31)
Net loss per share of common stock – diluted (in Dollars per share) $ (0.51) $ (0.31)
Weighted average shares of common stock outstanding – basic (in Shares) 31,195,891 27,886,486
Weighted average common shares outstanding – diluted (in Shares) 31,195,891 27,886,486
Revenue    
Revenue:    
Total revenue
Other Revenue    
Revenue:    
Total revenue